Research on Epitalon: Human Research, Clinical Trials and Preclinical Evidence

The peptide Epitalon, also known as Epithalon or AEDG (Ala-Glu-Asp-Gly), has been studied in cells of human origin, cultured human tissues, animals, non-human primates, and in a small number of older human studies. However, the overall body of evidence still relies mainly on preclinical and mechanistic research rather than modern randomised controlled human trials. [1]

The large volume of publications regarding Epitalon may give the impression that the peptide already has a mature clinical evidence base. However, this is not the case. A significant portion of the literature originates from cell cultures, studies on rodents, flies, birds, retina models, and rhesus macaques, and much of the early work was associated with Vladimir Khavinson and his colleagues. Data involving humans does exist, but its quality varies greatly and it must be clearly distinguished from research on Epithalamin, which is an older pineal peptide preparation. [1]

What Types of Research on Epitalon Have Been Published?

Published research on Epitalon includes in vitro experiments on human cells, ex vivo studies using cells harvested from humans, animal studies, experiments on non-human primates, molecular and computational studies, and a limited number of older human studies. However, the available literature conspicuously lacks large, contemporary randomised clinical trials of purified Epitalon. [1–8]

Research can be organised by the level of evidence, rather than simply counting publications.

This distinction is important because experiments on human cell lines are sometimes referred to online as „human trials”. Technically, the cells are of human origin, but the research itself is still in vitro, not a clinical trial involving humans. For example, a 2025 study which observed telomere lengthening and changes in hTERT used normal and cancerous human cell lines, rather than clinical trial participants. [2]

Similarly cultured lymphocytes taken from older donors provide ex vivo evidence from human material. In one such study, changes in chromatin organisation were noted following exposure to Epithalon, but the peptide was administered to cells in culture rather than systemically to the participants. [3]

Regarding the molecular results concerning hTERT, chromatin and telomerase, it is worth referring to the internal articles „Mechanism of Action of Epitalon: How This Peptide Works” and „Epitalon, Telomerase and Telomeres: What the Evidence Shows”.

Are there any randomised clinical trials of Epitalon in humans?

No robust contemporary randomised controlled trial on purified Epitalon was identified in the studies analysed or the databases currently being searched. One publication from 2002 concerning retinitis pigmentosa is indexed in PubMed as a „Clinical Trial”; however, its abstract does not provide information on randomisation, blinding, a control group, the number of participants, or sufficient details regarding the endpoints. [4]

This is one of the most important distinctions in the evidence base regarding Epitalon.

A 2002 paper by Khavinson et al. analysed Epitalon in Campbell rats and presented results in patients with degenerative retinal changes. PubMed classifies this work as a clinical trial. In the abstract, the authors state that a positive clinical effect was observed in 90% cases, but they do not specify the number of participants, the presence of a placebo or an untreated control group, the method of patient allocation, the blinding of investigators, or the method of defining „positive clinical effect”. [4]

The lack of this information makes it impossible to draw a firm conclusion regarding effectiveness.

Another source of confusion is Epithalamin. There are randomised human trials involving the peptide preparation Epithalamin. For example, a randomised trial of elderly people with cardiovascular disease was described as a 12-year clinical trial, whilst another publication followed a related cohort for 15 years. However, these studies concerned Epithalamin, a complex peptide preparation derived from the pineal gland, rather than the purified synthetic Epitalon/AEDG. They cannot be regarded as randomised trials of Epitalon.

The hierarchy of evidence should therefore clearly distinguish between:

Randomised clinical trials of Epithalamin ≠ randomised clinical trials of Epitalon.

This distinction prevents the apparent level of clinical evidence regarding Epitalon from being significantly overstated.

What Epitalon Human Studies Are Available?

The evidence regarding Epitalon in humans consists primarily of older, limited clinical observations, ex vivo studies using cells from elderly individuals, and in vitro experiments on human cells. The most frequently cited direct clinical publication concerns retinal degeneration, whilst most recent mechanistic findings originate from laboratories rather than patient studies. [2–6]

Major studies relevant to humans can be divided into several categories.

Older Retinal Clinical Trials

A 2002 publication, indexed as a clinical trial on retinitis pigmentosa, presented both data from Campbell rats and observations in humans. The authors reported that Epitalon produced a positive clinical effect in 90% patients with degenerative retinal changes. However, the abstract contains too little information about the study design to assess the magnitude of the effect, its reliability or the risk of systematic error. [4]

Therefore, this study should be described as a limited, older clinical signal rather than as definitive proof that Epitalon cures retinitis pigmentosa.

Lymphocyte and Chromatin Studies in Humans

One study used cultured leucocytes from individuals aged 75–88 years and analysed Epithalon along with several other short peptides. The researchers described ribosomal gene activation, chromatin decondensation and changes in specific heterochromatin regions. [3]

Because the cells were treated with the peptide outside the body, this is best classified as an ex vivo study on human cells.

Telomere Research in Human Fibroblasts

Early laboratory studies exposing normal human foetal fibroblasts to Epithalon demonstrated telomerase activation, telomere elongation and an increased replicative capacity. [5,6]

These experiments are biologically relevant, but they still constitute in vitro research on human cells, rather than proof that Epitalon lengthens telomeres in humans.

Contemporary Telomere Research in Human Cell Lines

In an in vitro study conducted in 2025, Al-Dulaimi and colleagues used normal fibroblasts and mammary gland epithelial cells, as well as two breast cancer cell lines. Epitalon increased hTERT expression and telomere length; an increase in telomerase activity was observed in normal cells, whilst a significant increase in ALT activity was observed in cancer cells. [2]

This study strengthens the molecular evidence for the relationship between Epitalon and telomere biology, while at the same time raising questions concerning differences between cell types and tumour biology.

Human Stem Cell Research

A 2020 study on human gingival mesenchymal stem cells reported increased expression of neuronal differentiation markers, including Nestin, GAP43, β-III tubulin and Doublecortin, following exposure to AEDG. [7]

Again, this was an in vitro experiment, not proof that Epitalon induces neurogenesis in the human brain.

Generally speaking, most „human Epitalon studies” can be more accurately described as research on cells of human origin rather than clinical trials involving humans.

What did animal lifespan studies show?

Animal lifespan studies have yielded mixed, although sometimes positive, results. Epitalon increased lifespan in some Drosophila and transgenic mouse models, and increased maximum survival or late-life survival in some rodent models. However, several studies showed little or no effect on median lifespan, demonstrating that the results depend on the species, strain, sex, and experimental conditions. [8–11]

One of the earliest studies on longevity used *Drosophila melanogaster*. Epitalon was administered during the developmental stage, and the lifespan of adult individuals increased by approximately 11–16% at several very low experimental concentrations. The effect did not follow a classic dose–response relationship. [8]

A study of HER-2/neu transgenic mice reported an increase in both mean and maximum lifespan, alongside a reduction in certain tumour-related parameters. [9] According to PubMed, in this particular model, the mean lifespan increased by approximately 13.5%, and the maximum lifespan by approximately 13.9%.

However, this is not a representative result for all animal experiments.

In female SHR mice of Swiss origin, long-term administration of Epitalon did not significantly increase average lifespan. However, it did increase maximum lifespan and survival rates among the longest-living 10% animals. [10]

Rat studies conducted under various lighting conditions also yielded condition-dependent effects. Under a normal day-night cycle, Epitalon sometimes had little effect on lifespan, whereas effects on maximum survival or late-life survivorship appeared under constant or seasonally varied lighting.

This matters because the statement „Epitalon extends the lifespan of animals” is technically true, but incomplete.

The more precise formulation is:

Epitalon increased lifespan or late-life survivorship in some animal models, while other models showed no improvement in mean lifespan.

Animal lifespan studies cannot confirm increased life expectancy in humans.

What did cellular and molecular research show?

Cellular and molecular studies have demonstrated an effect on telomerase, telomere length, hTERT expression, chromatin organisation, gene transcription, DNA interactions, oxidative stress pathways, mitochondrial markers, neuronal differentiation, retinal cells and inflammatory signalling. However, these findings remain mechanistic or preclinical and do not constitute proof of clinical benefit. [2,3,5–7,12–15]

Telomere research is among the most well-known.

Experiments on human fibroblasts demonstrated telomerase activation and telomere lengthening, whilst a 2025 study expanded on these observations by measuring hTERT mRNA, telomerase enzymatic activity, telomere length and ALT. [2,5,6]

Research into gene regulation is also generating a great deal of interest. Studies on human stem cells have shown changes in the expression of neurogenic markers, while experiments with cultured lymphocytes from elderly individuals have revealed changes in chromatin organisation. [3,7]

Biophysical studies suggest that Epithalon can penetrate cultured cells and cell nuclei and selectively interact with specific DNA oligonucleotide sequences. These results have contributed to the hypothesis that short peptides can influence transcription through direct or indirect interactions with chromatin.

Animal and cell studies have also demonstrated an effect on oxidative stress. Depending on the experimental model, changes in lipid peroxidation, reactive oxygen species levels, antioxidant enzyme activity, or the expression of genes related to antioxidant defence were observed.

These results support the conclusion that Epitalon is biologically active across a wide range of experimental systems.

However, they do not prove that the same pathways lead to measurable health benefits in humans.

Is Epitalon Registered on ClinicalTrials.gov?

As of August 2026, searching ClinicalTrials.gov for the exact terms „Epitalon” and „Epithalon” did not identify any registered interventional study directly evaluating the AEDG peptide. Search engines may return unrelated records containing similar strings, so the identity of the investigational intervention must be carefully verified.

ClinicalTrials.gov is operated by the US National Library of Medicine and includes registered clinical trials from many countries.

The current search did not find a study record directly testing Epitalon/Epithalon/AEDG.

One example shows why simple text matching can be misleading: the current ClinicalTrials.gov result for EPI-001 refers to autologous dermal papilla cell therapy used for androgenetic alopecia. It has nothing to do with Epitalon despite the superficially similar name „EPI”.

The lack of a record on ClinicalTrials.gov does not prove that no Epitalon trials in humans have ever been conducted. Some older studies pre-date modern clinical trial registration requirements, and historical research conducted outside jurisdictions requiring registration may not be visible there.

However, the absence of such records additionally indicates that no clear, contemporary clinical development programme for Epitalon is currently visible in the searched database.

As registries change over time, this status should be re-checked during subsequent publication updates.

How strong is the general evidence regarding Epitalon?

The evidence base for Epitalon is moderately broad, but weak in terms of clinical depth. There are numerous preclinical and mechanistic publications, several replicated cellular findings, studies in non-human primates, and limited older human observations. However, there is no contemporary clinical evidence base sufficient to confirm efficacy, optimal dosing, long-term safety, or longevity benefits in humans. [1–16]

The practical hierarchy of evidence is as follows:

Is Epitalon biologically active in laboratory systems?

Yes. And the body of available laboratory data provides moderately strong evidence for the biological activity of Epitalon. Published cellular, tissue, molecular and animal studies have demonstrated effects on, among other things, telomerase, gene expression, chromatin, oxidative stress pathways, melatonin-related signalling and other cellular processes.

Does Epitalon Affect Telomerase or Telomeres in Cultured Human Cells?

Yes. In many in vitro studies on human cells, an increase in telomerase activity, hTERT expression or telomere length has been observed following exposure to Epitalon. However, these results do not confirm that the same effect occurs in living humans.

Does Epitalon experimentally alter gene expression or chromatin?

Yes. Laboratory studies using cultured human cells and animal tissues have demonstrated changes in gene expression, ribosomal gene activity, heterochromatin organisation and other transcription-related processes following the administration of Epitalon. However, these effects remain experimental and have not been clinically confirmed.

Does Epitalon affect melatonin in animals or primates?

Probably so, but the results are not entirely consistent. Some studies on animals and non-human primates have shown an increase in nocturnal or evening melatonin levels and changes in circadian hormone rhythms. Conversely, at least one study on an isolated rat pineal gland showed no significant effect on melatonin secretion.

Does Epitalon Affect the Lifespan of Animals?

Yes, in some models. In selected studies on Drosophila, mice and rats, a longer maximum lifespan or better survival of animals at an advanced age was observed. However, other studies have shown little or no effect on average lifespan, so the overall data regarding animal longevity are mixed.

Are there direct clinical signals concerning Epitalon in humans?

Yes, but they are limited. There is a small number of older human observations and clinical reports, including studies on the retina and circadian rhythms. However, the study design, sample size, presence of control groups, and quality of reporting often fail to meet contemporary standards of clinical research.

Are There Contemporary Randomised Controlled Trials of Purified Epitalon?

No such robust study was identified in the analysed evidence. Older studies and work on related pineal peptide preparations exist, but they should not be confused with modern randomised controlled trials of purified Epitalon/AEDG.

Has Telomere Lengthening by Epitalon Been Confirmed in Living Humans?

No. Telomere lengthening has been demonstrated in cultured human cells, but it has not been established through controlled clinical trials that Epitalon lengthens telomeres in living humans.

Has it been proven that Epitalon extends human life?

No. Some animal studies have shown longevity-related effects, but there is no clinical evidence showing that Epitalon extends human life.

Is the long-term safety of Epitalon in humans established?

No. Long-term safety in humans remains uncertain due to a lack of large controlled studies, long-term follow-up, standardised reporting of adverse events, and robust pharmacovigilance data.

The strongest claims therefore relate to experimental biological effects.

The weakest relate to anti-ageing effects in humans.

This distinction is particularly important in the case of SEO phrases such as „Epitalon clinical trials”, „Epithalon research” or „Epitalon human study”. Search intent often assumes that the existence of a publication is synonymous with clinical validation, whilst the hierarchy of evidence encompasses a wide variety of research projects.

What are the main limitations of Epitalon research?

The main limitations include a lack of recent randomised trials involving humans, small or poorly described older clinical trials, a heavy reliance on animal and cellular models, concentrated authorship in the older literature, inconsistent study designs, widely varying doses and routes of administration, and a lack of standardised long-term data on safety and pharmacokinetics in humans. [1]

A few restrictions deserve special attention.

Firstly, the sample size and design of some older clinical trials are poorly described. The publication concerning retinitis pigmentosa is a good example: PubMed classifies it as a clinical trial, but the abstract provides neither the number of participants nor sufficient information regarding randomisation, blinding, control groups or the definition of endpoints. [4]

Secondly, many publications use endpoints in animal or cellular models instead of clinically relevant human outcomes. A longer telomere in fibroblast culture is not synonymous with an improvement in healthspan.

Thirdly, early research into Epitalon is concentrated around Vladimir Khavinson and associated institutions. This does not invalidate the work, but independent replication is important when evaluating the overall body of evidence.

Fourthly, the experiments use very different models and research exposures. The doses used in mice, intranasal administration in an anaesthetised rat, or direct exposure of a cell culture to a peptide cannot be simply translated into a validated protocol for humans.

Fifthly, some of the results are context-dependent or contradictory. In one study, isolated rat pineal glands showed no increase in melatonin secretion, whereas cultured pinealocytes and old rhesus macaques yielded positive results. Similarly, different lifespan and cancer models produced varying outcomes.

Finally, there are very few contemporary data regarding human pharmacokinetics, bioavailability, multiple exposure, drug interactions, reproductive safety, immunogenicity or long-term oncological outcomes.

These limitations make the literature better suited to generating hypotheses than to formulating established clinical recommendations.

Where Can Research on Epitalon Be Found?

Research on Epitalon can be found primarily in PubMed and PubMed Central, using the spelling variants „Epitalon”, „Epithalon”, „Epithalone” and „AEDG”. ClinicalTrials.gov should be searched separately for registered human studies, as scientific publication databases and clinical trial registries serve different functions.

PubMed is particularly useful because older literature often uses the name Epithalon, while newer publications more frequently use Epitalon.

Searching for just one variant of a name may therefore overlook some of the literature.

Useful academic search phrases include:

• Epitalon
• Epithalon
• Epithalone
• AEDG
• Ala-Glu-Asp-Gly
• Epitalon telomerase
• Epithalon melatonin
• AEDG chromatin
• Epitalon lifespan

PubMed records also help to distinguish the article type. For example, a publication concerning the retina is clearly indexed as a clinical trial, whereas the HER-2/neu study is unambiguously a mouse experiment, and the 2025 telomere study is a human cell line experiment.

ClinicalTrials.gov must be searched separately, because a published article and a registered clinical trial are not the same thing. The registry contains information about the study design, status, sponsor, number of participants, interventions, and other protocol elements, if the study was registered.

For readers seeking a general overview first, the review by Araj et al. from 2025 may be useful; it summarises more than two decades of literature on Epitalon, whilst also highlighting significant mechanistic and clinical uncertainties. [1]

General Summary of Evidence

Epitalon stands out amongst research peptides for its relatively long history of publication, spanning several decades.

Your story indeed covers interesting results: telomerase activation in cells of human origin, telomere elongation, gene expression changes, effects on chromatin, melatonin regulation, results regarding animal lifespan, retinal observations, and numerous endocrine and immunological effects.

However, the pyramid of evidence is inverted compared to a well-researched and approved medicine.

There is a substantial body of pre-clinical evidence and a limited amount of clinical evidence.

The available research allows Epitalon to be described as an experimentally active peptide with a number of proposed biological mechanisms. However, they do not justify presenting Epitalon as a clinically proven anti-ageing therapy that lengthens telomeres, improves sleep, treats retinal diseases, prevents cancer or prolongs life.

Disclaimer

This article is for educational and scientific-informational purposes only and does not constitute medical advice, diagnosis, therapeutic guidance, dosage instructions, or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) is not an approved therapy recognised by the FDA or EMA for anti-ageing applications, telomere lengthening, longevity, the treatment of sleep disorders, retinal diseases, or other applications discussed in this article. The available evidence base still relies primarily on cellular, animal, mechanistic, and other preclinical studies, with a limited number of human clinical data and a lack of a robust contemporary programme of randomised clinical trials identified in the analysed sources. For medical matters, a licensed healthcare professional should be consulted, and the current research and regulatory status should be verified in official databases such as ClinicalTrials.gov, the FDA, the EMA, and relevant national regulatory bodies.

References

[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691

[2] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178. https://doi.org/10.1007/s10522-025-10315-x

[3] Khavinson, V. K., Lezhava, T. A., Monaselidze, J. R., Jokhadze, T. A., Dvalishvili, N. A., Bablishvili, N. K., & Trofimova, S. V. (2003). Peptide Epitalon activates chromatin at old age. Neuro Endocrinology Letters, 24(5), 329–333. https://pubmed.ncbi.nlm.nih.gov/14647006/

[4] Khavinson, V., Razumovsky, M., Trofimova, S., Grigorian, R., & Razumovskaya, A. (2002). Pineal-regulating tetrapeptide Epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters, 23(4), 365–368. https://pubmed.ncbi.nlm.nih.gov/12195242/

[5] Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592. https://doi.org/10.1023/A:1025493705728

[6] Khavinson, V. K., Bondarev, I. E., Butyugov, A. A., & Smirnova, T. D. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine, 137(5), 503–506. https://doi.org/10.1023/B:BEBM.0000038164.49947.8C

[7] Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., & Sinjari, B. (2020). AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: Possible epigenetic mechanism. Molecules, 25(3), 609. https://doi.org/10.3390/molecules25030609

[8] Khavinson, V. K., Izmaylov, D. M., Obukhova, L. K., & Malinin, V. V. (2000). Effect of Epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development, 120(1–3), 141–149. https://doi.org/10.1016/S0047-6374(00)00217-7

[9] Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Semchenko, A. V., & Yashin, A. I. (2002). Epithalon decelerates ageing and suppresses development of breast adenocarcinomas in transgenic HER-2/neu mice. Bulletin of Experimental Biology and Medicine, 134(2), 187–190. https://doi.org/10.1023/A:1021104819170

[10] Anisimov, V. N., Khavinson, V. K., Popovich, I. G., Zabezhinski, M. A., Alimova, I. N., Rosenfeld, S. V., Zavarzina, N. Y., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of Epitalon on biomarkers of ageing, life span and spontaneous tumour incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202. https://doi.org/10.1023/A:1025114230714

[11] Vinogradova, I. A., Bukalev, A. V., Zabezhinski, M. A., Semenchenko, A. V., Khavinson, V. K., & Anisimov, V. N. (2007). Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumours in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine, 144(6), 825–830. https://doi.org/10.1007/s10517-007-0441-z

[12] Fedoreyeva, L. I., Kireev, I. I., Khavinson, V. K., & Vanyushin, B. F. (2011). Penetration of short fluorescence-labelled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11), 1210–1219. https://doi.org/10.1134/S0006297911110022

[13] Gatta, M., Dovizio, M., Milillo, C., Ruggieri, A. G., Sallese, M., Antonucci, I., Trofimov, A., Khavinson, V., Trofimova, S., Bruno, A., & Ballerini, P. (2025). The antioxidant tetrapeptide Epitalon enhances delayed wound healing in an in vitro model of diabetic retinopathy. Stem Cell Reviews and Reports, 21(6), 1822–1834. https://doi.org/10.1007/s12015-025-10911-x

[14] Goncharova, N. D., Khavinson, V. K., & Lapin, B. A. (2001). Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bulletin of Experimental Biology and Medicine, 131(4), 394–396. https://doi.org/10.1023/A:1017928925177

[15] Djeridane, Y., Khavinson, V. K., Anisimov, V. N., & Touitou, Y. (2003). Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. Journal of Endocrinological Investigation, 26(3), 211–215. https://doi.org/10.1007/BF03345159

[16] Khavinson, V. K. (2002). Peptides and ageing. Neuro Endocrinology Letters, 23(Suppl. 3), 11–144. https://pubmed.ncbi.nlm.nih.gov/12374906/